CA2007507A1 - Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules - Google Patents
Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellulesInfo
- Publication number
- CA2007507A1 CA2007507A1 CA2007507A CA2007507A CA2007507A1 CA 2007507 A1 CA2007507 A1 CA 2007507A1 CA 2007507 A CA2007507 A CA 2007507A CA 2007507 A CA2007507 A CA 2007507A CA 2007507 A1 CA2007507 A1 CA 2007507A1
- Authority
- CA
- Canada
- Prior art keywords
- sphingosine
- methyl
- pharmaceutically acceptable
- prepared
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 title abstract 5
- 230000010261 cell growth Effects 0.000 title abstract 5
- PTGGMPLMNDBPGB-CXISOLTFSA-N n-[(e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl]formamide Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC=O PTGGMPLMNDBPGB-CXISOLTFSA-N 0.000 title abstract 5
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 8
- 210000004102 animal cell Anatomy 0.000 abstract 4
- 230000012010 growth Effects 0.000 abstract 4
- 239000003966 growth inhibitor Substances 0.000 abstract 4
- 210000005260 human cell Anatomy 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000003408 sphingolipids Chemical class 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30637889A | 1989-02-03 | 1989-02-03 | |
| US306,378 | 1989-02-03 | ||
| US39013589A | 1989-08-07 | 1989-08-07 | |
| US390,135 | 1989-08-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2007507A1 true CA2007507A1 (fr) | 1990-08-03 |
| CA2007507C CA2007507C (fr) | 1998-05-19 |
Family
ID=26975128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002007507A Expired - Fee Related CA2007507C (fr) | 1989-02-03 | 1990-01-10 | Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0381514B1 (fr) |
| JP (1) | JP2976055B2 (fr) |
| AT (1) | ATE122560T1 (fr) |
| CA (1) | CA2007507C (fr) |
| DE (1) | DE69019388T2 (fr) |
| DK (1) | DK0381514T3 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583160A (en) * | 1989-02-03 | 1996-12-10 | The Biomembrane Institute | Methylsphingosine used to treat apoptosis |
| US5151360A (en) * | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
| US5260288A (en) * | 1992-04-03 | 1993-11-09 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives |
| IL121320A (en) | 1997-02-23 | 2000-12-06 | Ibr Ltd | Extracts from cells or tissue of organisms which are capable of entering dormancy for inhibition of proliferation of target cells or tissue |
| US6800661B1 (en) | 1997-04-15 | 2004-10-05 | Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
| US6107520A (en) * | 1997-04-15 | 2000-08-22 | The Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
| USRE38793E1 (en) | 1997-04-15 | 2005-09-06 | Rinehart Kenneth L | Spisulosine compounds |
| AUPO900297A0 (en) * | 1997-09-08 | 1997-10-02 | Medvet Science Pty. Ltd. | A method of modulating cellular activity |
| US6649362B2 (en) | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
| MXPA02007995A (es) * | 2000-02-16 | 2003-05-23 | Ruffles Graham Keith | Derivados de tetrahidrofurilo sustituidos por oxy y amino con actividad antitumoral. |
| EP1195604A1 (fr) * | 2000-09-29 | 2002-04-10 | Warner-Lambert Company | Procedés et compositions pour la sondage de modulateurs de lipide kinases |
| WO2002060405A1 (fr) * | 2001-01-29 | 2002-08-08 | Cosmoferm B.V. | Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide |
| KR100457113B1 (ko) * | 2001-12-27 | 2004-11-16 | 한국원자력연구소 | 세라마이드류 또는 그 유도체와 다이메틸스핑고신을 유효성분으로 포함하는 방사선민감도 증진제 |
| KR100459484B1 (ko) * | 2002-05-20 | 2004-12-03 | 한국원자력연구소 | 엔-아세틸 파이토스핑고신과 다이메틸 파이토스핑고신을유효 성분으로 포함하는 방사선 치료 민감제 조성물 |
| EP1426053A1 (fr) * | 2002-12-03 | 2004-06-09 | Fresenius Kabi Deutschland GmbH | Utilisation de lipides amphiphiles pour l'inhibition de métastases |
| ATE539741T1 (de) | 2004-11-30 | 2012-01-15 | Tno | Sphingolipide bei der behandlung und prävention von hepatischer steatose |
| JP2013510878A (ja) * | 2009-11-12 | 2013-03-28 | テキサス テック ユニバーシティー | 高増殖性障害を処置する組成物および方法 |
| TWI807411B (zh) | 2017-04-27 | 2023-07-01 | 西班牙商瑪製藥股份有限公司 | 抗腫瘤化合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
-
1990
- 1990-01-10 CA CA002007507A patent/CA2007507C/fr not_active Expired - Fee Related
- 1990-02-02 EP EP90301099A patent/EP0381514B1/fr not_active Expired - Lifetime
- 1990-02-02 DE DE69019388T patent/DE69019388T2/de not_active Expired - Fee Related
- 1990-02-02 AT AT90301099T patent/ATE122560T1/de not_active IP Right Cessation
- 1990-02-02 DK DK90301099.9T patent/DK0381514T3/da active
- 1990-02-02 JP JP2025010A patent/JP2976055B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69019388D1 (de) | 1995-06-22 |
| DE69019388T2 (de) | 1996-01-04 |
| EP0381514A2 (fr) | 1990-08-08 |
| JPH03157336A (ja) | 1991-07-05 |
| JP2976055B2 (ja) | 1999-11-10 |
| CA2007507C (fr) | 1998-05-19 |
| EP0381514A3 (fr) | 1991-07-17 |
| EP0381514B1 (fr) | 1995-05-17 |
| ATE122560T1 (de) | 1995-06-15 |
| DK0381514T3 (da) | 1995-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2007507A1 (fr) | Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules | |
| TW334432B (en) | Tricyclic amide and urea compounds | |
| CA2296036A1 (fr) | Derives de dolastatine 15 | |
| MX9707732A (es) | Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas. | |
| MX9707562A (es) | Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas. | |
| TW376319B (en) | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine | |
| MY119350A (en) | Propiophenone derivatives and process for preparing the same | |
| CA2257121A1 (fr) | Methodes et compositions pour le traitement de l'incontinence urinaire utilisant (s)-oxybutynine | |
| CA2293706A1 (fr) | Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase | |
| ZA907338B (en) | Thienylcarboxylates of amino alcohols | |
| MX9707665A (es) | Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas. | |
| GR3034974T3 (en) | Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin | |
| MX9803809A (es) | Inhibidores de hidroxamato de bifenilo de metaloproteinasas de matriz. | |
| AU7239996A (en) | Inhibition of tumor necrosis factor alpha | |
| CA2047744A1 (fr) | Methode de synthese de l'huperzine a et de ses analogues et composes utilises pour ce faire | |
| MY143570A (en) | Compounds useful for inhibition of farnesyl protein transferase | |
| PL326554A1 (en) | Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase | |
| MY103871A (en) | 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis. | |
| NO944407L (no) | Alkoholer som kalium-kanalåpnere og ved behandling av urin-inkontinens | |
| PL320342A1 (en) | Thrombin inhibitor containing infusion solution, stable during storage | |
| GB9410639D0 (en) | Method of improving fertilization | |
| AU644621B2 (en) | Pharmaceutical composition for treating or preventing retroviral infections | |
| DE69926078D1 (en) | Farnesyl-protein transferase inhibitoren | |
| CA2293358A1 (fr) | Sulfonamides tricycliques servant a inhiber la farnesyl-proteine transferase | |
| EP0328420A3 (fr) | Gangliosides contenant l'acide de-N-acétylsiatique et leur utilisation comme modificateurs de la physiologie des cellules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |